The FDA has approved a new indication for Ozempic (semaglutide; Novo Nordisk) injection to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) do not appear to increase the risk of acute kidney injury (AKI), according to the findings of a recently published systematic review and meta-analysis. To evaluate the risk of AKI with these agents, study authors reviewed literature analyzing the effect of SGLT2is on renal adverse events compared with placebo or other…
Increased risk for heart failure also seen in group of participants without diastolic dysfunction.
Diabetes-specific financial stress predicts engagement in trading, receiving donated meds, supplies.
For patients with type 2 diabetes, apparent treatment-resistant hypertension increases risk for cardiovascular events and mortality.
Long-standing diabetes linked to higher risk for both all-cause and cardiovascular mortality.
Rates of early-onset CVD higher for offspring of mothers with history of CVD, diabetes complications.
No metformin recalls affect US market at the moment.
Risks increased for all-cause mortality, cardiovascular events, microvascular complications.
Researchers assessed the risk for gout among adults receiving a sodium-glucose cotransporter 2 inhibitor vs a glucagon-like peptide-1 receptor agonist.
